In this study, we present in vitro data for targeting of the BMP2-SMAD1/5/8 pathway in combination with inhibition of the MEK-ERK pathway as a treatment strategy for MPNST patients. The gene discussed is SMAD1; the disease is malignant peripheral nerve sheath tumor.